Selective Elimination of Culture-Adapted Human Embryonic Stem Cells with BH3 Mimeticsopen access
- Authors
- Cho, Seung-Ju; Kim, Keun-Tae; Jeong, Ho-Chang; Park, Ju-Chan; Kwon, Ok-Seon; Song, Yun-Ho; Shin, Joong-Gon; Kang, Seungmin; Kim, Wankyu; Shin, Hyoung Doo; Lee, Mi-Ok; Moon, Sung-Hwan; Cha, Hyuk-Jin
- Issue Date
- Nov-2018
- Publisher
- CELL PRESS
- Keywords
- BCL-xL; BCL2L1; BH3 mimetics; CTRP; culture adaptation; survival advantage; YM155
- Citation
- STEM CELL REPORTS, v.11, no.5, pp 1244 - 1256
- Pages
- 13
- Journal Title
- STEM CELL REPORTS
- Volume
- 11
- Number
- 5
- Start Page
- 1244
- End Page
- 1256
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/69809
- DOI
- 10.1016/j.stemcr.2018.09.002
- ISSN
- 2213-6711
- Abstract
- The selective survival advantage of culture-adapted human embryonic stem cells (hESCs) is a serious safety concern for their clinical application. With a set of hESCs with various passage numbers, we observed that a subpopulation of hESCs at late passage numbers was highly resistant to various cell death stimuli, such as YM155, a survivin inhibitor. Transcriptome analysis from YM155-sensitive (YM155S) and YM155-resistant (YM155R) hESCs demonstrated that BCL2L1 was highly expressed in YM155R hESCs. By matching the gene signature of YM155R hESCs with the Cancer Therapeutics Response Portal dataset, BH3 mimetics were predicted to selectively ablate these cells. Indeed, short-course treatment with a sub-optimal dose of BH3 mimetics induced the spontaneous death of YM155R, but not YM155S hESCs by disrupting the mitochondrial membrane potential. YM155S hESCs remained pluripotent following BH3 mimetics treatment. Therefore, the use of BH3 mimetics is a promising strategy to specifically eliminate hESCs with a selective survival advantage.
- Files in This Item
-
- Appears in
Collections - ETC > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/69809)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.